Keros Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $222.3M
- Price
- $11.21
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.82%
- Volume
- 196.0K
About
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
Quick stats
Shares outstanding19.8M
Computed float18.5M
Float / shares93.1%
Cash runway (months)42
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001664710
Websitehttps://www.kerostx.com
AI Summary
AI-generated1/18
standardbullishoperations update
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
Keros Therapeutics expects a $20 million development milestone payment from partner Takeda after the first patient was dosed in the ELRiSE MF Phase 3 trial of elritercept in myelofibrosis.
Keros will distribute 25% of the net cash proceeds to stockholders following receipt. Under the January 2025 license, Keros already received a $200 million upfront and is eligible for milestones potentially exceeding $1.1 billion plus tiered royalties.
The trial tests elritercept versus placebo in myelofibrosis patients with anemia on concurrent ruxolitinib therapy, keeping the Takeda-partnered program on track.